StockData

Humacyte vs Outlook Therapeutics

HUMA and OTLK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

humaHumacyte$0.56−55.3% in 1 yearotlkOutlook Therapeutics$0.41−67.7% in 1 year

How HUMA and OTLK compare

Humacyte is the larger company, worth 1.5 times as much as Outlook Therapeutics ($155M against $101M).

Outlook Therapeutics scores higher on the StockData Score (4 against 2 for Humacyte), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHUMAOTLK
Size and price
Market cap$155M$101M
Share price$0.558$0.413
Change, 1 year−55.3%−67.7%
Change, 5 years−94.9%−98.7%
Beta (5Y)2.060.97
Employees18417
StockData Score
Total score24 (better)
Valuation score00
Growth score1 (better)0
Performance score00
Health score14 (better)
Dividend score00
Valuation
P/S64.7×–
P/B8.6×–
FCF yield−57.1%–
Growth
Revenue growth (TTM)52.5%–
Profitability
Gross margin−475%–
Operating margin−4603%–
Net margin−3955%–
FCF margin−3697%–
Return on equity−1424%–
Financial health
Interest coverage−11.0×–
Current ratio3.34 (better)0.81
Altman Z-score−10.34 (better)−40.56
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield–−54.4%
Shareholder yield0.00% (better)−54.4%
Ownership
Held by institutions26.4%8.4%
Held by insiders8.0%28.5%
Insider net buying, 12 months$7.4K$7.9M (better)
Short interest, % of float11.0%20.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.